Announced
Completed
Synopsis
Samsung Biologics, a South Korean biotechnology company, completed the acquisition of the remaining 50% stake in Samsung Bioepis joint venture from Biogen, an American multinational biotechnology company based in Cambridge, for $2.3bn. "We are thankful to Samsung Biologics for a productive collaboration since 2012. We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen," Michel Vounatsos, Biogen CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.